| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/22/2007 | WO2006029219A3 Human monoclonal anti-ctla4 antibodies in cancer treatment |
| 02/22/2007 | WO2005121338A9 Anti-perp antibody |
| 02/22/2007 | WO2005089518A3 Uch-l1 expression and cancer therapy |
| 02/22/2007 | WO2005042725A3 Liver cancer biomarkers |
| 02/22/2007 | WO2005036123A3 Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
| 02/22/2007 | WO2004098491A3 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
| 02/22/2007 | WO2004094467A3 H. pylori antigens |
| 02/22/2007 | WO2004074436A3 Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer |
| 02/22/2007 | US20070043210 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/22/2007 | US20070043055 Dihydropteridinones in the treatment of respiratory diseases |
| 02/22/2007 | US20070042981 Use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 02/22/2007 | US20070042980 Gp131: methods and compositions for treating cancer |
| 02/22/2007 | US20070042977 Vaccine |
| 02/22/2007 | US20070042947 Agents for preventing and/or treating uppper digestive tract disorders |
| 02/22/2007 | US20070042945 Nouvelles compositions et methods de traitement du psoriasis |
| 02/22/2007 | US20070042471 Homogeneous preparations of il-28 and il-29 |
| 02/22/2007 | US20070042470 Homogeneous preparations of il-28 and il-29 |
| 02/22/2007 | US20070042469 Homogeneous preparations of IL-29 produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins which has antihepatitis activity |
| 02/22/2007 | US20070042447 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) |
| 02/22/2007 | US20070042446 Drug screening; for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 02/22/2007 | US20070042383 for detecting Mycobacterium paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies; for immunization and prevention of mycobacterial animal infections |
| 02/22/2007 | US20070042341 Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpopulations and in cryopreservation, culture and transplantation of cells |
| 02/22/2007 | US20070042050 Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression |
| 02/22/2007 | US20070042048 Devices, Compositions and Methods for the Pulmonary Delivery of Aerosolized Medicaments |
| 02/22/2007 | US20070042047 Vaccines |
| 02/22/2007 | US20070042005 Pharmaceutical composition comprising fungal cell or fragment thereof |
| 02/22/2007 | US20070042004 Methods of Treating A Bacterial Infection using F. Tularensis Lipopolysaccharide |
| 02/22/2007 | US20070042003 Method of effecting a mammalian model of sepsis, severe sepsis, or septic shock |
| 02/22/2007 | US20070042002 Influenza recombinant subunit vaccine |
| 02/22/2007 | US20070042001 Influenza recombinant subunit vaccine |
| 02/22/2007 | US20070042000 Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142 |
| 02/22/2007 | US20070041999 Production of multivalent virus like particles |
| 02/22/2007 | US20070041998 Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses |
| 02/22/2007 | US20070041997 Bacterial virulence factors and uses thereof |
| 02/22/2007 | US20070041992 Compositions and methods for inactivating or suppressing inflammatory cells |
| 02/22/2007 | US20070041991 amino acid sequence proteins or immunogenic fragments, encoded sequence from isolated nucleic acid; for treating infection caused from Babesiidae; diagnostic test for the detection of nucleic acids, antibodies or antigens of the organism; safe, stable, easily scaleable production; veterinary medicine |
| 02/22/2007 | US20070041990 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 02/22/2007 | US20070041989 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 02/22/2007 | US20070041988 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 02/22/2007 | US20070041987 Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development |
| 02/22/2007 | US20070041986 Synthetic polysaccharide antigens for immunological intervention in disease |
| 02/22/2007 | US20070041985 Modulation of the poliovirus receptor function |
| 02/22/2007 | US20070041984 Novel methods of cancer diagnosis and therapy targeted against a cancer stem line |
| 02/22/2007 | US20070041983 Method for treating tumors using anti-osteopontin antibodies |
| 02/22/2007 | US20070041982 ILT3 binding molecules and uses therefor |
| 02/22/2007 | US20070041981 Compositions and methods for altering immune function |
| 02/22/2007 | US20070041980 CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/22/2007 | US20070041979 Proteolysis resistant antibody preparations |
| 02/22/2007 | US20070041978 Bispecific antibody substituting for functional proteins |
| 02/22/2007 | US20070041977 Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof |
| 02/22/2007 | US20070041976 Treating septic arthritis; Interleukin-4 (IL-4), previously known as B cell stimulating factor |
| 02/22/2007 | US20070041975 Homogeneous preparations of il-28 and il-29 |
| 02/22/2007 | US20070041974 Cytokine zalpha11 ligand antibodies |
| 02/22/2007 | US20070041973 Compositions and methods for treating, preventing and/or reversing type-1 diabetes |
| 02/22/2007 | US20070041972 Antibodies and fusion proteins that include engineered constant regions |
| 02/22/2007 | US20070041971 Methods for predicting development of auto-immune diseases and treatment of same |
| 02/22/2007 | US20070041970 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
| 02/22/2007 | US20070041969 Apo-2DcR |
| 02/22/2007 | US20070041968 Methods of inducing an immune response |
| 02/22/2007 | US20070041967 Igg fc fragment for a drug carrier and method for the preparation thereof |
| 02/22/2007 | US20070041966 Polypeptides including modified constant regions |
| 02/22/2007 | US20070041965 Novel dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 02/22/2007 | US20070041964 WISP polypeptides and nucleic acids encoding same |
| 02/22/2007 | US20070041963 Human secreted proteins |
| 02/22/2007 | US20070041956 Vaccine immunotherapy for immune suppressed patients |
| 02/22/2007 | US20070041945 Novel method for down-regulation of amyloid |
| 02/22/2007 | US20070041941 Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same |
| 02/22/2007 | US20070041940 Methods of treating cancer using il-21 |
| 02/22/2007 | US20070041939 Modified cytokines for use in cancer therapy |
| 02/22/2007 | US20070041936 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/22/2007 | US20070041907 Immunoglobulin molecules with improved characteristics |
| 02/22/2007 | US20070041905 Method of treating depression using a TNF-alpha antibody |
| 02/22/2007 | US20070041901 2'-O-methyl substituted nucleic acids specific to prostate specific membrane antigen (PSMA) for use in detection and targeting cancer tissues |
| 02/22/2007 | CA2656705A1 Influenza recombinant subunit vaccine |
| 02/22/2007 | CA2619777A1 Detecting molecular complexes |
| 02/22/2007 | CA2619763A1 Fas binding antibodies |
| 02/22/2007 | CA2619751A1 Rotavirus vaccine inducing heterotypic cross protection |
| 02/22/2007 | CA2619725A1 Single chain antibodies against beta-amyloid peptide |
| 02/22/2007 | CA2619716A1 Antigenic peptides and their use |
| 02/22/2007 | CA2619695A1 Therapy with cd4 binding peptides and radiation |
| 02/22/2007 | CA2619245A1 Chimeric antibodies with new world primate regions |
| 02/22/2007 | CA2619244A1 Engineered antibodies with new world primate framework regions |
| 02/22/2007 | CA2619174A1 Immunization of avians by administration of non-replicating vectored vaccines |
| 02/22/2007 | CA2618920A1 Human monoclonal antibodies that specifically bind igf-ii |
| 02/22/2007 | CA2618783A1 Vaccination against dengue virus infection |
| 02/22/2007 | CA2618508A1 Truncated memapsin 2 for use for treating alzheimer's disease |
| 02/22/2007 | CA2556473A1 Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith |
| 02/21/2007 | EP1754788A2 Prostate-specific membrane antigen and uses thereof |
| 02/21/2007 | EP1754719A2 Anti-osteopontin antibody and use thereof |
| 02/21/2007 | EP1754717A1 Antigenic peptides and their use |
| 02/21/2007 | EP1754715A1 Vaccine on the basis of virus-neutralising antibodies |
| 02/21/2007 | EP1754490A2 CD 154 blockage therapy for pancreatic islet tissue transplantation in primates |
| 02/21/2007 | EP1753882A2 Gene expression and polymorphisms associated with lung cancer |
| 02/21/2007 | EP1753871A2 Antibodies and related molecules that bind to psca proteins |
| 02/21/2007 | EP1753845A2 Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system |
| 02/21/2007 | EP1753507A1 Combination of radio waves and pharmacologically active substances |
| 02/21/2007 | EP1753465A1 Assay for transmissible spongiform encephalopathies |
| 02/21/2007 | EP1753463A2 Antibody drug conjugates and methods |
| 02/21/2007 | EP1753456A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 02/21/2007 | EP1753455A2 Method for treating multiple sclerosis |